Emergent BioSolutions (EBS) News Today $4.62 +0.04 (+0.94%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$4.77 +0.15 (+3.18%) As of 04/15/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Trexquant Investment LP Has $6.71 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)Trexquant Investment LP boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 59.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 701,517 shares of the biopharmacApril 6, 2025 | marketbeat.comEmergent BioSolutions rises 11.8%April 2, 2025 | markets.businessinsider.comEmergent BioSolutions (NYSE:EBS) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday.April 2, 2025 | marketbeat.comEmergent BioSolutions (NYSE:EBS) to Repurchase $50.00 million in SharesEmergent BioSolutions (NYSE:EBS - Get Free Report) declared that its Board of Directors has authorized a stock buyback plan on Monday, March 31st, RTT News reports. The company plans to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 19% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its shares are undervalued.April 1, 2025 | marketbeat.comEmergent BioSolutions announces $50M stock repurchase programApril 1, 2025 | markets.businessinsider.comEmergent BioSolutions rises 9.0%April 1, 2025 | markets.businessinsider.comEmergent BioSolutions Announces Stock Repurchase ProgramMarch 31, 2025 | globenewswire.comAmerican Century Companies Inc. Increases Stake in Emergent BioSolutions Inc. (NYSE:EBS)American Century Companies Inc. grew its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 23.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,137,712 shares of the biopharmaceutical company's stock after buying an additional 404,667 shaMarch 31, 2025 | marketbeat.comEmergent BioSolutions: I See Further Downside Ahead In This Value TrapMarch 26, 2025 | seekingalpha.comQ1 Earnings Forecast for EBS Issued By HC WainwrightEmergent BioSolutions Inc. (NYSE:EBS - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Emergent BioSolutions in a research note issued to investors on Friday, March 21st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will postMarch 24, 2025 | marketbeat.comEmergent BioSolutions (NYSE:EBS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a report on Friday.March 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Reduces Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Charles Schwab Investment Management Inc. lessened its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 42.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,290,230 shares of the biopharmaceuticalMarch 22, 2025 | marketbeat.comEmergent BioSolutions sells Baltimore facility to SyngeneMarch 21, 2025 | investing.comExpert Outlook: Emergent BioSolutions Through The Eyes Of 5 AnalystsMarch 21, 2025 | benzinga.comEmergent Biosolutions’ Strategic Investments and Divestitures Justify Buy RatingMarch 21, 2025 | tipranks.comEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08March 20, 2025 | globenewswire.comHikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mgMarch 20, 2025 | globenewswire.comEmergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalMarch 19, 2025 | globenewswire.comEmergent BioSolutions announces $27M in incremental salesMarch 19, 2025 | markets.businessinsider.comEmergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure ProductsMarch 18, 2025 | globenewswire.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 902,332 shares of the biopharmaceutical companMarch 16, 2025 | marketbeat.comEmergent BioSolutions reinforces commitment to expanding access to NARCANMarch 13, 2025 | markets.businessinsider.comEmergent BioSolutions Inc. (NYSE:EBS) Director Sells $204,050.00 in StockEmergent BioSolutions Inc. (NYSE:EBS - Get Free Report) Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 13, 2025 | marketbeat.comEmergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness ProgramsMarch 13, 2025 | globenewswire.comEmergent BioSolutions, Rocketvax announce investment agreementMarch 12, 2025 | markets.businessinsider.comEmergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product CandidatesMarch 12, 2025 | globenewswire.comDrug manufacturer to sell Baltimore plant for $36.5MMarch 10, 2025 | bizjournals.comEmergent BioSolutions to sell Baltimore-Bayview facility for $36.5MMarch 10, 2025 | markets.businessinsider.comIndia's Syngene International acquires first US biologics facility for $50 mlnMarch 10, 2025 | reuters.comEmergent BioSolutions to sell Baltimore-Bayview manufacturing site for $36.5MMarch 10, 2025 | msn.comEmergent BioSolutions Inc. Agrees to Sell Baltimore-Bayview Manufacturing Facility to Syngene International for $36.5 MillionMarch 10, 2025 | quiverquant.comEmergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalMarch 10, 2025 | globenewswire.comPrescott Group Capital Management L.L.C. Has $2.01 Million Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Prescott Group Capital Management L.L.C. lifted its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 250.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,000 shares of the bMarch 8, 2025 | marketbeat.comBrokers Issue Forecasts for EBS Q1 EarningsEmergent BioSolutions Inc. (NYSE:EBS - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Emergent BioSolutions in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company wilMarch 7, 2025 | marketbeat.comEmergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to "Hold"StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday.March 6, 2025 | marketbeat.comEmergent BioSolutions Inc. (NYSE:EBS) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMarch 6, 2025 | finance.yahoo.comEmergent BioSolutions falls -24.6%March 4, 2025 | markets.businessinsider.comEmergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | msn.comEmergent BioSolutions (EBS) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | msn.comEmergent BioSolutions (NYSE:EBS) Given "Buy" Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday.March 4, 2025 | marketbeat.comEmergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | seekingalpha.comAfter-hours movers: Okta, GitLab, New Fortress Energy, Emergent BioSolutionsMarch 3, 2025 | in.investing.comEmergent BioSolutions Inc. (NYSE:EBS) is favoured by institutional owners who hold 64% of the companyMarch 3, 2025 | finance.yahoo.comEmergent BioSolutions sees Q1 revenue $200M-$240M, consensus $279MMarch 3, 2025 | markets.businessinsider.comEmergent Biosolutions Non-GAAP EPS of $0.05 beats by $0.55, revenue of $194.7M misses by $59.97MMarch 3, 2025 | seekingalpha.comEmergent BioSolutions (NYSE:EBS) Announces Quarterly Earnings ResultsEmergent BioSolutions (NYSE:EBS - Get Free Report) released its quarterly earnings data on Monday. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%.March 3, 2025 | marketbeat.comEmergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 3, 2025 | globenewswire.comEmergent Biosolutions Q4 2024 Earnings PreviewMarch 2, 2025 | seekingalpha.comEmergent BioSolutions Inc. (NYSE:EBS) Stake Raised by New York State Common Retirement FundNew York State Common Retirement Fund grew its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 41.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,286 shares of theMarch 2, 2025 | marketbeat.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Sold by Truist Financial CorpTruist Financial Corp reduced its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,193 shares of the biopharmaceutical company's stock aMarch 2, 2025 | marketbeat.com Remove Ads Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Media Mentions By Week EBS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EBS News Sentiment▼1.720.78▲Average Medical News Sentiment EBS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EBS Articles This Week▼05▲EBS Articles Average Week Remove Ads Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPK News GERN News MYGN News ZBIO News RIGL News VNDA News VSTM News XOMA News CDXS News SGMO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:EBS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EBS Stock Free EBS Stock Alerts